269 related articles for article (PubMed ID: 32645298)
1. Spatiotemporal PET Imaging Reveals Differences in CAR-T Tumor Retention in Triple-Negative Breast Cancer Models.
Volpe A; Lang C; Lim L; Man F; Kurtys E; Ashmore-Harris C; Johnson P; Skourti E; de Rosales RTM; Fruhwirth GO
Mol Ther; 2020 Oct; 28(10):2271-2285. PubMed ID: 32645298
[TBL] [Abstract][Full Text] [Related]
2. PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors.
Murty S; Labanieh L; Murty T; Gowrishankar G; Haywood T; Alam IS; Beinat C; Robinson E; Aalipour A; Klysz DD; Cochran JR; Majzner RG; Mackall CL; Gambhir SS
Cancer Res; 2020 Nov; 80(21):4731-4740. PubMed ID: 32958548
[TBL] [Abstract][Full Text] [Related]
3. Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer.
Dees S; Ganesan R; Singh S; Grewal IS
Mol Cancer Ther; 2020 Dec; 19(12):2409-2421. PubMed ID: 33087511
[TBL] [Abstract][Full Text] [Related]
4. Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer.
Wei H; Wang Z; Kuang Y; Wu Z; Zhao S; Zhang Z; Li H; Zheng M; Zhang N; Long C; Guo W; Nie C; Yang H; Tong A
Front Immunol; 2020; 11():573823. PubMed ID: 33072116
[TBL] [Abstract][Full Text] [Related]
5. CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.
Zhou R; Yazdanifar M; Roy LD; Whilding LM; Gavrill A; Maher J; Mukherjee P
Front Immunol; 2019; 10():1149. PubMed ID: 31178870
[TBL] [Abstract][Full Text] [Related]
6. Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography.
Sakemura R; Cox MJ; Bansal A; Roman CM; Hefazi M; Vernon CJ; Glynn DL; Pandey MK; DeGrado TR; Siegler EL; Kenderian SS
J Vis Exp; 2022 Feb; (180):. PubMed ID: 35253798
[TBL] [Abstract][Full Text] [Related]
7. Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET.
Simonetta F; Alam IS; Lohmeyer JK; Sahaf B; Good Z; Chen W; Xiao Z; Hirai T; Scheller L; Engels P; Vermesh O; Robinson E; Haywood T; Sathirachinda A; Baker J; Malipatlolla MB; Schultz LM; Spiegel JY; Lee JT; Miklos DB; Mackall CL; Gambhir SS; Negrin RS
Clin Cancer Res; 2021 Feb; 27(4):1058-1068. PubMed ID: 33087332
[TBL] [Abstract][Full Text] [Related]
8. A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers.
Wei J; Sun H; Zhang A; Wu X; Li Y; Liu J; Duan Y; Xiao F; Wang H; Lv M; Wang L; Wu C
Cell Immunol; 2018 Sep; 331():49-58. PubMed ID: 29935762
[TBL] [Abstract][Full Text] [Related]
9. Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition.
Xia L; Zheng Z; Liu JY; Chen YJ; Ding J; Hu GS; Hu YH; Liu S; Luo WX; Xia NS; Liu W
Cancer Immunol Res; 2021 Jun; 9(6):707-722. PubMed ID: 33875483
[TBL] [Abstract][Full Text] [Related]
10. Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level.
Song DG; Ye Q; Poussin M; Chacon JA; Figini M; Powell DJ
J Hematol Oncol; 2016 Jul; 9(1):56. PubMed ID: 27439908
[TBL] [Abstract][Full Text] [Related]
11. Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer.
Hu Z
Sci Rep; 2020 Feb; 10(1):2815. PubMed ID: 32071339
[TBL] [Abstract][Full Text] [Related]
12. Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor.
Liu Y; Zhou Y; Huang KH; Fang X; Li Y; Wang F; An L; Chen Q; Zhang Y; Shi A; Yu S; Zhang J
Cell Prolif; 2020 Aug; 53(8):e12858. PubMed ID: 32592435
[TBL] [Abstract][Full Text] [Related]
13. Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity.
Sakemura R; Bansal A; Siegler EL; Hefazi M; Yang N; Khadka RH; Newsom AN; Hansen MJ; Cox MJ; Manriquez Roman C; Schick KJ; Can I; Tapper EE; Nevala WK; Adada MM; Bezerra ED; Kankeu Fonkoua LA; Horvei P; Ruff MW; Parikh SA; Pandey MK; DeGrado TR; Suksanpaisan L; Kay NE; Peng KW; Russell SJ; Kenderian SS
Cancer Immunol Res; 2021 Sep; 9(9):1035-1046. PubMed ID: 34244299
[TBL] [Abstract][Full Text] [Related]
14. Targeting Stage-Specific Embryonic Antigen 4 (SSEA-4) in Triple Negative Breast Cancer by CAR T Cells Results in Unexpected on Target/off Tumor Toxicities in Mice.
Pfeifer R; Al Rawashdeh W; Brauner J; Martinez-Osuna M; Lock D; Herbel C; Eckardt D; Assenmacher M; Bosio A; Hardt OT; Johnston ICD
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298141
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
16. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies.
Niu Z; Wu J; Zhao Q; Zhang J; Zhang P; Yang Y
Front Immunol; 2024; 15():1385571. PubMed ID: 38680498
[TBL] [Abstract][Full Text] [Related]
17. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.
Hung CF; Xu X; Li L; Ma Y; Jin Q; Viley A; Allen C; Natarajan P; Shivakumar R; Peshwa MV; Emens LA
Hum Gene Ther; 2018 May; 29(5):614-625. PubMed ID: 29334771
[TBL] [Abstract][Full Text] [Related]
18. Expression of CD22 in Triple-Negative Breast Cancer: A Novel Prognostic Biomarker and Potential Target for CAR Therapy.
Zaib T; Cheng K; Liu T; Mei R; Liu Q; Zhou X; He L; Rashid H; Xie Q; Khan H; Xu Y; Sun P; Wu J
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768478
[TBL] [Abstract][Full Text] [Related]
19. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
20. Radionuclide-based molecular imaging allows CAR-T cellular visualization and therapeutic monitoring.
Shao F; Long Y; Ji H; Jiang D; Lei P; Lan X
Theranostics; 2021; 11(14):6800-6817. PubMed ID: 34093854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]